Trans Tasman Radiation Oncology Group
52
2
8
34
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
1.9%
1 terminated/withdrawn out of 52 trials
97.1%
+10.6% vs industry average
37%
19 trials in Phase 3/4
12%
4 of 34 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (52)
Primary Radiotherapy In MEtastatic Lung Cancer
Role: lead
A Study of Standard Of Care Versus Radio Ablation in Early Stage HCC
Role: collaborator
Stereotactic Prostate Adaptive Radiotherapy Utilising Kilovoltage Intrafraction Monitoring
Role: collaborator
Magnetic Resonance Imaging (MRI) Guided Stereotactic Adaptive Radiotherapy for Targeting Abdominal Cancer
Role: collaborator
Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer
Role: collaborator
Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy
Role: lead
Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA
Role: lead
Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma
Role: collaborator
Neurotropic Melanoma of the Head and Neck
Role: collaborator
A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases
Role: lead
Study Comparing Stereotactic Body Radiotherapy vs Conventional Palliative Radiotherapy (CRT) for Spinal Metastases
Role: collaborator
Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme
Role: collaborator
Single vs Multiple-Fraction Therapy in Treating Patients With Previously Irradiated Painful Bone Metastases
Role: collaborator
Radiation Therapy in Treating Women Who Have Undergone Surgery for Early-Stage Invasive Breast Cancer
Role: collaborator
Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast Cancer
Role: collaborator
Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the Breast
Role: lead
A Study of Local Therapy for the Treatment of Brain Metastases From HER2 Positive Breast Cancer
Role: lead
Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma
Role: lead
Radiotherapy - Adjuvant Versus Early Salvage
Role: lead
Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney
Role: lead